Is There a Generic Semaglutide? What to Know in 2026
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not generics and are not the same as brand-name products such as Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound. They may differ in formulation, purity, and potency.
If you have been searching for a generic version of your GLP-1 medication to bring the cost down, here is the honest answer: as of October 16, 2026, FDA’s records list no approved generic semaglutide or tirzepatide in the US. One generic semaglutide injection has tentative approval, which does not allow it to be sold yet. Compounded medication is sometimes confused with a generic, but it is not the same thing.
The short answer
We checked FDA’s Drugs@FDA database on October 16, 2026[1]. Here is what it shows:
- Semaglutide: the only approved products are Novo Nordisk’s brand-name products: Ozempic injection, Wegovy injection and tablets, and Rybelsus and Ozempic tablets[1][2][3]. One generic application, Apotex’s ANDA 220314 for semaglutide injection pens (2 mg/3 mL, 4 mg/3 mL, and 8 mg/3 mL), received tentative approval on April 7, 2026[4]. Under FDA’s definition, a tentative approval means the generic is ready for approval but FDA delays final approval until patent or exclusivity issues are resolved, and the company cannot market it[5].
- Tirzepatide: the only approved products are Eli Lilly’s brand-name Mounjaro and Zepbound. Drugs@FDA lists no generic tirzepatide application, approved or tentatively approved[1].
Drugs@FDA shows approved and tentatively approved applications only. Applications still under FDA review are not public, so other companies may have generic applications pending.
You may have seen the word “generic” used loosely online, sometimes attached to lower-cost telehealth offers. That usage is inaccurate and, in marketing, a known compliance problem. What those programs typically offer is compounded medication, which is a different category with a different regulatory status. The rest of this page explains the difference so you can make a decision based on what is actually true.
Generic vs brand vs compounded: what the difference actually is
These three terms get used interchangeably, but they mean very different things. Getting the distinction right matters, because it affects what you are actually paying for and how it has been reviewed.
Brand-name medication is the original, FDA-approved product made by the company that developed it. It went through FDA review for safety, effectiveness, and quality, and it is sold under a registered trademark. Ozempic, Wegovy, and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide) fall into this category.
A generic is an FDA-approved copy of a brand-name medication. Other manufacturers can apply to make one through FDA’s abbreviated new drug application (ANDA) pathway. According to FDA, a generic must match the brand-name drug in active ingredient, strength, dosage form, and route of administration, must be bioequivalent to it, and is made under the same quality standards[6]. Patents and exclusivities on the brand-name product can delay when a generic can be approved and sold[6].
A compounded medication is prepared by a state-licensed compounding pharmacy or an FDA-registered outsourcing facility, based on a prescription written by a licensed provider. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed[7]. FDA answers the question “Are compounded drugs and generic drugs the same?” with a plain no: a generic is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act, while a compounded drug is not approved by FDA[7]. Compounded semaglutide may differ from brand-name products in formulation, purity, and potency, and it is not “the same as” or “equivalent to” a brand-name product. FDA has also warned that some compounded semaglutide uses salt forms (semaglutide sodium and semaglutide acetate), which are different active ingredients from the one in the approved drugs[8].
The simplest way to hold it in your head: a generic is an FDA-approved copy that can be sold only once patent and exclusivity issues are resolved. Compounded medication is something a pharmacy prepares under different rules, without FDA approval.
Why there is no generic yet
The reason comes down to patent and exclusivity protections. When a company develops a new medication, it can hold patents and periods of marketing exclusivity that delay when competitors can sell approved copies[6].
FDA’s Orange Book lists these protections for each product. In the Orange Book data files FDA published in October 2026[9]:
- For Ozempic and Wegovy injection, the listed patents include one FDA flags as covering the drug substance, with an expiration date of December 5, 2031. Other listed patents run as late as 2041.
- For Mounjaro and Zepbound, the listed patents include a drug-substance patent with an expiration date of May 13, 2036, and new chemical entity exclusivity listed through May 13, 2027. Other listed patents run as late as 2039 (Zepbound) and 2041 (Mounjaro).
A listed patent date is not a launch date. Patents can be challenged in court, settled, or held invalid, and companies sometimes agree on entry dates that are not public. That is why you should be cautious of any source that claims to know an exact generic launch date. We do not predict one.
So if you are waiting for a cheaper FDA-approved generic to appear, the accurate picture is that it is not available now and the timeline is uncertain. That leaves a practical question: what are your options today?
What this means if you are looking for a lower-cost option
You came here looking to lower your cost, and that goal is completely reasonable. Brand-name GLP-1 medications can be expensive without insurance, and the price depends on the product, the dose, and where the prescription is filled. A generic would help, but none is on the market yet.
People looking for a lower cost usually compare a few routes: insurance coverage (including prior authorization), the manufacturers’ self-pay programs for brand-name products, and telehealth programs that prescribe brand-name or compounded medication. At most telehealth programs, you complete a health history, and a licensed provider decides whether a GLP-1 medication is appropriate for you. If it is, the prescription is filled by a pharmacy, which may be a retail pharmacy for brand-name products or a compounding pharmacy for compounded ones, and the provider follows up over time.
Compounded medication is not a generic, and we want to be precise about that. It is not FDA-approved, and FDA does not review it for safety, effectiveness, or quality[7]. Its availability has also changed. FDA determined that the semaglutide injection shortage was resolved on February 21, 2025, and the tirzepatide injection shortage on December 19, 2024; FDA’s page on its compounding policies was last updated April 1, 2026[10]. With both off the shortage list, compounding of these drugs is limited by federal and state pharmacy law, and availability cannot be guaranteed. Our page on whether compounded GLP-1 is still available covers the details.
If you want to read more about the regulatory side, our overview of compounded GLP-1 medications covers the framework, and our page on compounded semaglutide safety explains how to tell a licensed provider from an unsafe online seller. For a broader cost comparison, see GLP-1 medication without insurance and the medication pricing overview.
What it costs
Prices vary by program and dose. Some programs bundle medication, provider visits, labs, and shipping into one monthly price; others bill for some of these separately or raise the price as the dose increases. Before you choose, compare the total cost: medication at your likely dose, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms. Confirm in writing what the price covers.
For more on what drives compounded program pricing, see our guide to compounded semaglutide cost.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedImportant disclosures
This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
As of October 16, 2026, FDA’s Drugs@FDA database lists no approved generic semaglutide or tirzepatide. One generic semaglutide injection application (ANDA 220314) has tentative approval, which does not allow it to be marketed. Compounded medications are not generics and are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they may differ from brand-name products in formulation, purity, and potency.
Regulatory status is subject to change. The FDA determined that the tirzepatide injection shortage was resolved on December 19, 2024, and that the semaglutide injection shortage was resolved on February 21, 2025. FDA has posted later updates to its compounding policy, most recently dated April 1, 2026; check the FDA page for the current statement[10].
This page does not predict when any generic may become available. Patent and exclusivity dates come from FDA’s Orange Book and are not launch dates.
Citations
[1] U.S. Food and Drug Administration. Drugs@FDA data files (Products and Submissions tables). https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files (Downloaded and checked 2026-10-16. Supports: approved semaglutide and tirzepatide applications; no approved generic of either; no tirzepatide ANDA listed.)
[2] U.S. Food and Drug Administration. RYBELSUS and OZEMPIC (semaglutide) tablets, prescribing information. Revised 1/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051Orig1s030lbl.pdf (Supports: Rybelsus and Ozempic tablets share one FDA-approved label.)
[3] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Supports: Wegovy injection and tablets are FDA-approved.)
[4] U.S. Food and Drug Administration. Drugs@FDA: ANDA 220314, Apotex Inc, semaglutide injection. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220314 (Accessed 2026-10-16. Supports: tentative approval on 04/07/2026; strengths; marketing status “None (Tentative Approval)”.)
[5] U.S. Food and Drug Administration. “Drugs@FDA Glossary of Terms,” entry “Tentative Approval.” https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms (Accessed 2026-10-16. Supports: meaning of tentative approval; no marketing allowed.)
[6] U.S. Food and Drug Administration. “Generic Drug Facts.” Content current as of 11/01/2021. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts (Accessed 2026-10-16. Supports: what a generic is; bioequivalence; patents and exclusivities affect generic timing.)
[7] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs are not FDA-approved; FDA does not verify their safety, effectiveness, or quality; compounded drugs are not generics.)
[8] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: salt-form warning.)
[9] U.S. Food and Drug Administration. Orange Book data files (patent.txt and exclusivity.txt). https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files (Files dated 2026-10-09, downloaded 2026-10-16. Supports: listed patent and exclusivity expiration dates for NDA 209637, 215256, 215866, and 217806.)
[10] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: shortage resolution dates.)
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded semaglutide and tirzepatide are not FDA-approved and are not generic drugs. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound and may differ in formulation, purity, and potency. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Ozempic, Wegovy, and Rybelsus are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.